Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by 3woodon May 12, 2008 12:38pm
732 Views
Post# 15063410

Confused

ConfusedGuys I don't understand the recent price decrease.Shouldn't we look upon the blackout asa positive that a deal must be near? They must have given the TSE a reason and it can't be for an indefinite time ( does anyone know exactly how long the extention was ) , we have a solid team of scientists ( world class even ) and that a big drug company is running out of patients plus we know there have been negiotions. I ca understand a big deal taking a long time but even the rumor of a deal should have driven the price over $20 - afterall it almost hit $30 on nothing more than a rumor. Does anyone have a reasonable idea where the negiotioations stand and what kind of share price is being considered. From what I had heard a deal was done in early April @ $40 plus - it turns out wrong but did sound realistic.   
Bullboard Posts